Table 1 Patient’s demographics and clinical characteristics at baselinea as a function of azithromycin treatment response
From: Azithromycin and the microbiota of cystic fibrosis sputum
| Relative | |||
|---|---|---|---|
| Responder (n = 17) | Non-Responder (n = 21) | P-value | |
| Demographicsb | |||
| Sex (Male:Female) | 7:10 | 7:14 | 0.739 |
| Age (years) | 26.06 (21.9–29.9) | 25.2 (20.7–30.4) | 0.964 |
| ∆F508 / ∆F508 | 9 (52.9) | 10 (47.6) | 1 |
| FEV1% predicted | 44 (32–62) | 56 (40–78) | 0.270 |
| FVC % predicted | 71 (64–87) | 87 (67–99) | 0.171 |
| Body mass index (kg/m2) | 20.1 (18.8–21.4) | 20.6 (18.9–22.1) | 0.402 |
| CF related diseasesb | |||
| Pancreatic sufficiency | 2 (11.7) | 3 (14.2) | 1 |
| CF-related diabetes | 4 (23.5) | 1 (4.7) | 0.152 |
| CF-liver disease | 4 (23.5) | 2 (9.5) | 0.378 |
| Osteopenia/Osteoporosis | 5 (29.4) | 10 (47.6) | 0.326 |
| Cultured pathogenb | |||
| Pseudomonas aeruginosa | 13 (76.4) | 15 (71.4) | 1 |
| Staphylococcus aureus | 6 (35.2) | 7 (33.3) | 1 |
| Haemophilus influenzae | 1 (5.8) | 1 (4.7) | 1 |
| Stenotrophomonas maltophilia | 2 (11.7) | 1 (4.7) | 0.576 |
| Escherichia coli | 1 (5.8) | 1 (4.7) | 1 |
| Therapiesb | |||
| Inhaled DNase | 12 (70.5) | 12 (57.1) | 0.506 |
| Inhaled colistin | 0 (0) | 1 (4.7) | 1 |
| Inhaled tobramycin | 6 (35.2) | 7 (33.3) | 1 |
| Inhaled hypertonic saline | 5 (29.4) | 9 (42.8) | 0.506 |
| Proton pump inhibitor | 4 (23.5) | 9 (42.8) | 0.307 |
| Inhaled corticosteroids | 15 (88.2) | 9 (42.8) | 0.006 |
| Long-acting bronchodilator | 16 (94.1) | 17 (80.9) | 0.355 |
| Short-acting bronchodilator | 12 (70.5) | 15 (71.4) | 1 |
| Pancreatic enzymes | 15 (88.2) | 18 (85.7) | 1 |
| Ranitidine | 4 (23.5) | 1 (4.7) | 0.152 |
| CFTR-modulator | 0 (0) | 0 (0) | – |